Summary of Study ST001266
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000851. The data can be accessed directly via it's Project DOI: 10.21228/M8PH4S This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST001266 |
| Study Title | Metabolomic Profiles of Pancreatic β-Cells and Islets Exposed to Arsenic, part I β-Cells |
| Study Summary | Type-2 diabetes (T2D) is a complex metabolic disorder that affects hundreds of millions of people world-wide and is a growing public health concern. Despite recent advances in T2D research, the etiology of this disease and the mechanisms underlying the metabolic defects remain poorly understood. While obesity is thought to be the main cause for the rising prevalence of T2D, obesity alone cannot explain differences in the trends of T2D among different geographical regions and populations. Growing evidence suggests that environmental exposures to toxic and diabetogenic substances must play important roles. Inorganic arsenic (iAs) is a naturally occurring toxic metalloid. Hundreds of millions of people worldwide are exposed to unsafe levels of iAs in drinking water and food. iAs is a potent carcinogen, but iAs exposure has also been linked to increase risk of T2D. While the link between iAs exposure and T2D is well-established, the mechanisms underlying the diabetogenic effects of iAs exposure remain unclear. Results of our previously published and ongoing studies suggest that pancreatic β-cells are a primary target for iAs and its metabolites and that impaired insulin secretion by β-cells is the mechanism by which iAs exposure leads to diabetes. The proposed project will use metabolomics to identify metabolic pathways in β-cells that are targeted by iAs and its metabolites, monomethyl-As (MAs) and dimethyl-As (DMAs). The metabolomics data combined with results of our ongoing mechanistic studies will provide a comprehensive picture of the metabolic dysfunction leading to the development of diabetes in individuals exposed to iAs and of the molecular mechanisms that underlie this dysfunction. Identifying the affected pathways and mechanisms will ultimately help to improve strategies for prevention and/or treatment of T2D associated with chronic exposure to iAs. |
| Institute | University of North Carolina |
| Last Name | Sumner |
| First Name | Susan |
| Address | 500 Laureate Way, Kannapolis, NC 28081 |
| Susan_sumner@unc.edu | |
| Phone | (919)6224456 |
| Submit Date | 2019-04-15 |
| Raw Data File Type(s) | raw(Thermo) |
| Analysis Type Detail | LC-MS |
| Release Date | 2020-06-20 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Factors:
Subject type: Cultured cells; Subject species: Mus musculus (Factor headings shown in green)
| mb_sample_id | local_sample_id | Cell Type | Treatment |
|---|---|---|---|
| SA092008 | SP_CB_1_1 | Beta cell sample pool | - |
| SA092009 | SP_CB_1_2 | Beta cell sample pool | - |
| SA092010 | SP_CB_2_2 | Beta cell sample pool | - |
| SA092011 | SP_CB_2_1 | Beta cell sample pool | - |
| SA092012 | SP_CB_3_1 | Beta cell sample pool | - |
| SA092013 | SP_CB_3_2 | Beta cell sample pool | - |
| SA092014 | SP_CB_4 | Beta cell sample pool | - |
| SA092025 | CB_16 | INS-1 (beta cells) | dimethylated arsenic |
| SA092026 | CB_40 | INS-1 (beta cells) | dimethylated arsenic |
| SA092027 | CB_36 | INS-1 (beta cells) | dimethylated arsenic |
| SA092028 | CB_37 | INS-1 (beta cells) | dimethylated arsenic |
| SA092029 | CB_38 | INS-1 (beta cells) | dimethylated arsenic |
| SA092030 | CB_17 | INS-1 (beta cells) | dimethylated arsenic |
| SA092031 | CB_18 | INS-1 (beta cells) | dimethylated arsenic |
| SA092032 | CB_20 | INS-1 (beta cells) | dimethylated arsenic |
| SA092033 | CB_39 | INS-1 (beta cells) | dimethylated arsenic |
| SA092034 | CB_19 | INS-1 (beta cells) | dimethylated arsenic |
| SA092035 | CB_7 | INS-1 (beta cells) | inorganic arsenic (sodium arsenite) |
| SA092036 | CB_9 | INS-1 (beta cells) | inorganic arsenic (sodium arsenite) |
| SA092037 | CB_8 | INS-1 (beta cells) | inorganic arsenic (sodium arsenite) |
| SA092038 | CB_6 | INS-1 (beta cells) | inorganic arsenic (sodium arsenite) |
| SA092039 | CB_30 | INS-1 (beta cells) | inorganic arsenic (sodium arsenite) |
| SA092040 | CB_28 | INS-1 (beta cells) | inorganic arsenic (sodium arsenite) |
| SA092041 | CB_26 | INS-1 (beta cells) | inorganic arsenic (sodium arsenite) |
| SA092042 | CB_10 | INS-1 (beta cells) | inorganic arsenic (sodium arsenite) |
| SA092043 | CB_29 | INS-1 (beta cells) | inorganic arsenic (sodium arsenite) |
| SA092044 | CB_27 | INS-1 (beta cells) | inorganic arsenic (sodium arsenite) |
| SA092045 | CB_13 | INS-1 (beta cells) | monomethylated arsenic |
| SA092046 | CB_12 | INS-1 (beta cells) | monomethylated arsenic |
| SA092047 | CB_11 | INS-1 (beta cells) | monomethylated arsenic |
| SA092048 | CB_34 | INS-1 (beta cells) | monomethylated arsenic |
| SA092049 | CB_14 | INS-1 (beta cells) | monomethylated arsenic |
| SA092050 | CB_15 | INS-1 (beta cells) | monomethylated arsenic |
| SA092051 | CB_32 | INS-1 (beta cells) | monomethylated arsenic |
| SA092052 | CB_35 | INS-1 (beta cells) | monomethylated arsenic |
| SA092053 | CB_33 | INS-1 (beta cells) | monomethylated arsenic |
| SA092054 | CB_31 | INS-1 (beta cells) | monomethylated arsenic |
| SA092015 | CB_25 | INS-1 (beta cells) | No treatment |
| SA092016 | CB_3 | INS-1 (beta cells) | No treatment |
| SA092017 | CB_1 | INS-1 (beta cells) | No treatment |
| SA092018 | CB_24 | INS-1 (beta cells) | No treatment |
| SA092019 | CB_4 | INS-1 (beta cells) | No treatment |
| SA092020 | CB_5 | INS-1 (beta cells) | No treatment |
| SA092021 | CB_23 | INS-1 (beta cells) | No treatment |
| SA092022 | CB_21 | INS-1 (beta cells) | No treatment |
| SA092023 | CB_2 | INS-1 (beta cells) | No treatment |
| SA092024 | CB_22 | INS-1 (beta cells) | No treatment |
| Showing results 1 to 47 of 47 |
